The efficiency of Botox and Xeomin, two of the most popular botulinum toxin type A fillers in the U.S., was the subject of recent studies in Dermatology Times and Cosmetic Surgery Times. The two injectables were scrutinized on their effects on glabellar, or frown lines, in three tests.

In the final, head-to-head trial, Botox and Xeomin were determined equivalent after one month, with similar results occurring in the second month after treatment, with 97% of patients satisfied at one month.
The Trials
The publications reached out to over 8,000 physicians to poll the differences found between six sets of images of patients before and 30 days after treatment, three each depicting patients injected with Botox or Xeomin. 60–65% could not distinguish which toxin had been used, while those who chanced an answer were incorrect between 24–73% of the time.
Read more at Skin Inc Magazine's Medical Spa Newsletter >>